Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Richard S. Finn | Researchclopedia

Back to researchers

Richard S. Finn

University of California, Los Angeles ORCID

760

Works

81,109

Citations

101

h-index

275

i10-index

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research

Affiliations

AstraZeneca (United Kingdom)2010–2010

Northwestern University2012–2024

University of Southern California2006–2013

Santa Monica College2014–2023

University of Modena and Reggio Emilia2011–2011

Top Works

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn,Shukui Qin,et al.

20206,928 citations

Cancer Immunotherapy and Biomarkers

Pancreatic and Hepatic Oncology Research

Hepatocellular carcinoma

Josep M. Llovet,Robin Kate Kelley,et al.

20216,205 citations

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo,Richard S. Finn,et al.

20185,313 citations

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Jorge A. Marrero,Laura Kulik,et al.

20184,525 citations

AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K. Heimbach,Laura Kulik,et al.

20174,122 citations

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix,Shukui Qin,et al.

20163,613 citations

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn,Miguel Martín,et al.

20162,882 citations

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu,Richard S. Finn,et al.

20182,498 citations

Molecular therapies and precision medicine for hepatocellular carcinoma

Josep M. Llovet,Robert Montal,et al.

20181,980 citations